Show
Sort by
-
- Journal Article
- A1
- open access
Etanercept withdrawal and retreatment in nonradiographic axial spondyloarthritis : results of RE-EMBARK, an open-label phase IV trial
-
- Journal Article
- A1
- open access
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis : results from a phase III, randomised, double-blind, placebo-controlled trial
-
Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies
-
- Journal Article
- A1
- open access
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
-
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V) : 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
-
Measurement properties of the ASAS Health Index : results of a global study in patients with axial and peripheral spondyloarthritis
-
Effects of long-term etanercept treatment on clinical outcomes and objective signs of inflammation in early nonradiographic axial spondyloarthritis : 104-week results from a randomized, placebo-controlled study
-
- Journal Article
- A1
- open access
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force